Bioo Scientific

www.biooscientific.com

Bioo Scientific Corporation is an Austin, TX based biotechnology company that provides innovative solutions for food and feed safety testing, next generation sequencing (NGS) library prep and other life science research. Founded in 2003, Bioo Scientific’s novel technology is protected by current and pending patents worldwide.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

SESEN BIO PARTNERS WITH HIKMA PHARMACEUTICALS FOR THE REGISTRATION AND COMMERCIALIZATION OF VICINEUM

Sesen Bio | December 02, 2020

news image

Sesen Bio, a late-stage clinical organization creating focused on combination protein therapeutics for the therapy of patients with cancer, and Hikma Pharmaceuticals, a worldwide pharmaceutical organization and driving permitting partner in the Middle East and North Africa ("MENA") area spend significant time in the turn of events and commercialization of an expansive scope of great medicines, today declared that the organizations have gone into exclusive licensing agreement for the re...

Read More

Cell and Gene Therapy

EMERGENT BIOSOLUTIONS COMPLETES ACQUISITION OF EXCLUSIVE WORLDWIDE RIGHTS TO TEMBEXA® FIRST FDA-APPROVED SMALLPOX ORAL ANTIVIRAL FOR ALL AGES

TEMBEXA and Smallpox | September 27, 2022

news image

Emergent BioSolutions Inc. announced that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® the first oral antiviral approved by the U.S. Food and Drug Administration for all age groups for the treatment of smallpox, from Chimerix. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The completion of the acquisition follows the satisfaction or waiver by the ...

Read More

MedTech

CARL ZEISS MEDITEC AND PRECISE BIO ANNOUNCE PARTNERSHIP IN THE DEVELOPMENT AND COMMERCIALIZATION OF TISSUE-BASED IMPLANTS FOR OPHTHALMOLOGY

Precise Bio | July 19, 2022

news image

Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced today that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction.&n...

Read More

RELAY THERAPEUTICS ANNOUNCES FORMATION OF ONCOLOGY ADVISORY BOARD

BioSpace | March 04, 2020

news image

Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, announced today the appointment of top oncology experts, scientists and leaders to its newly formed oncology advisory board. “We are at a pivotal moment in the company’s growth and development as we become a clinical-stage company and we are delighted to have such an esteemed group of leaders to advise and support our team,” said Don Bergstrom, M.D., Ph.D., executive vice pre...

Read More
news image

Medical

SESEN BIO PARTNERS WITH HIKMA PHARMACEUTICALS FOR THE REGISTRATION AND COMMERCIALIZATION OF VICINEUM

Sesen Bio | December 02, 2020

Sesen Bio, a late-stage clinical organization creating focused on combination protein therapeutics for the therapy of patients with cancer, and Hikma Pharmaceuticals, a worldwide pharmaceutical organization and driving permitting partner in the Middle East and North Africa ("MENA") area spend significant time in the turn of events and commercialization of an expansive scope of great medicines, today declared that the organizations have gone into exclusive licensing agreement for the re...

Read More
news image

Cell and Gene Therapy

EMERGENT BIOSOLUTIONS COMPLETES ACQUISITION OF EXCLUSIVE WORLDWIDE RIGHTS TO TEMBEXA® FIRST FDA-APPROVED SMALLPOX ORAL ANTIVIRAL FOR ALL AGES

TEMBEXA and Smallpox | September 27, 2022

Emergent BioSolutions Inc. announced that it has completed its acquisition of exclusive worldwide rights to TEMBEXA® the first oral antiviral approved by the U.S. Food and Drug Administration for all age groups for the treatment of smallpox, from Chimerix. TEMBEXA was approved in June 2021 and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. The completion of the acquisition follows the satisfaction or waiver by the ...

Read More
news image

MedTech

CARL ZEISS MEDITEC AND PRECISE BIO ANNOUNCE PARTNERSHIP IN THE DEVELOPMENT AND COMMERCIALIZATION OF TISSUE-BASED IMPLANTS FOR OPHTHALMOLOGY

Precise Bio | July 19, 2022

Carl Zeiss Meditec and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, announced today that the companies have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction.&n...

Read More
news image

RELAY THERAPEUTICS ANNOUNCES FORMATION OF ONCOLOGY ADVISORY BOARD

BioSpace | March 04, 2020

Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, announced today the appointment of top oncology experts, scientists and leaders to its newly formed oncology advisory board. “We are at a pivotal moment in the company’s growth and development as we become a clinical-stage company and we are delighted to have such an esteemed group of leaders to advise and support our team,” said Don Bergstrom, M.D., Ph.D., executive vice pre...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us